Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

IMPC-051-01

Supelco

Theophylline solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C7H8N4O2
CAS-Nummer:
58-55-9
Molekulargewicht:
180.16
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

certified reference material

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

1.0 mg/mL in methanol

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

pharmaceutical (small molecule)

Format

single component solution

Lagertemp.

2-8°C

SMILES String

CN1C(=O)N(C)c2nc[nH]c2C1=O

InChI

1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)

InChIKey

ZFXYFBGIUFBOJW-UHFFFAOYSA-N

Angaben zum Gen

human ... ADORA1(134) , ADORA2A(135) , ADORA2B(136) , ADORA3(140) , PDE3A(5139) , PDE3B(5140) , PDE4A(5141) , PDE4B(5142) , PDE4C(5143) , PDE4D(5144)

Allgemeine Beschreibung

A Certified Spiking Solution® suitable for use as starting material in the preparation of calibrators and controls for theophylline testing methods by LC-MS/MS or GC-MS. Theophylline, also known as dimethylxanthine, is a naturally occurring stimulant of the xanthine family. Sold under the trade name Theolair, theophylline is used for treatment of asthma and other respiratory diseases.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes,Central nervous system

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 2

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup

Zulassungslistungen

Zulassungslistungen werden hauptsächlich für chemische Produkte erstellt. Für nicht-chemische Produkte können hier nur begrenzte Angaben gemacht werden. Kein Eintrag bedeutet, dass keine der Komponenten gelistet ist. Es liegt in der Verantwortung des Benutzers, die sichere und legale Verwendung des Produkts zu gewährleisten.

EU REACH Annex XVII (Restriction List)

CAS No.

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 5

1 of 5

Lamotrigine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-019

Lamotrigine solution

Over-The-Counter Multi-Component Mixture-6 solution 100 μg/mL in acetonitrile (of each analyte), ampule of 1 mL, certified reference material, Cerilliant®

Supelco

O-034

Over-The-Counter Multi-Component Mixture-6 solution

Koffein -Lösung 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-051

Koffein -Lösung

Theophyllin United States Pharmacopeia (USP) Reference Standard

USP

1653004

Theophyllin

Levetiracetam -Lösung 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-020

Levetiracetam -Lösung

Bing Dai et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 60(3), 360-370 (2012-04-21)
Whether treatment with adenosine receptor antagonists such as theophylline can prevent contrast-induced acute kidney injury (AKI) remains controversial. We conducted a meta-analysis of randomized controlled trials using MEDLINE (1966 to July 2011), EMBASE (1980 to July 2011), Web of Science
Mazen Al-Alawi et al.
The American journal of medicine, 127(5), 370-378 (2014-01-02)
Global estimates on aging predict an increased burden of asthma in the older population. Consequently, its recognition, diagnosis, and management in clinical practice require optimization. This review aims to provide an update for clinicians, highlighting advances in the understanding of
F S F Ram et al.
Respiratory medicine, 99(2), 135-144 (2005-02-18)
To determine the efficacy of oral theophylline compared with placebo in people with stable chronic obstructive pulmonary disease (COPD). Systematic review of randomized-controlled trials comparing oral theophylline with placebo for a minimum of 7 days in people with stable COPD.
Victoria Boswell-Smith et al.
The Journal of allergy and clinical immunology, 117(6), 1237-1243 (2006-06-06)
Theophylline has been relegated to a second- or even third-line therapy in the treatment of asthma and chronic obstructive pulmonary disease (COPD), behind glucocorticosteroids and beta2-agonists, although recent findings have suggested that theophylline possesses anti-inflammatory and immunomodulatory effects in addition
David J Henderson-Smart et al.
The Cochrane database of systematic reviews, (1)(1), CD000273-CD000273 (2010-01-22)
Recurrent apnea is common in preterm infants, particularly at very early gestational ages. These episodes of loss of effective breathing can lead to hypoxemia and bradycardia, which may be severe enough to require resuscitation including use of positive pressure ventilation.
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.